

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
9.1	14.04.2025	52737-00021	Date of first issue: 02.02.2015

Section 1: Identification

Product name : Interferon Alfa-2b Solid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800
CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

Section 2: Hazard identification**GHS Classification**

Reproductive toxicity : Category 1

Specific target organ toxicity - repeated exposure : Category 2 (Blood, Bone marrow)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360FD May damage fertility. May damage the unborn child.
H373 May cause damage to organs (Blood, Bone marrow)
through prolonged or repeated exposure.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protec-
tion/ face protection.

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
9.1	14.04.2025	52737-00021	Date of first issue: 02.02.2015

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Interferon alfa-2b	98530-12-2	>= 1 -< 10

Section 4: First-aid measures

- | | |
|---|--|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| If inhaled | : If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists. |
| If swallowed | : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : Dust contact with the eyes can lead to mechanical irritation.
May damage fertility. May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : Treat symptomatically and supportively. |

Section 5: Fire-fighting measures

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.1	14.04.2025	52737-00021	03.12.2024
			Date of first issue: 02.02.2015

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Metal oxides
Phosphorus compounds
Oxides of phosphorus
Carbon dioxide (CO₂)
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Section 6: Accidental release measures

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.1	14.04.2025	52737-00021	03.12.2024
			Date of first issue: 02.02.2015

employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

- | | | |
|-----------------------------|---|---|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |
| Conditions for safe storage | : | Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types:
Strong oxidizing agents |

Section 8: Exposure controls/personal protection**Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
------------	---------	----------------------------------	--	-------

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.1	14.04.2025	52737-00021	03.12.2024
			Date of first issue: 02.02.2015

Interferon alfa-2b	98530-12-2	TWA	0.2 µg/m ³ (OEB 5)	Internal
		Wipe limit	2 µg/100 cm ²	Internal

Engineering measures : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
9.1	14.04.2025	52737-00021	Date of first issue: 02.02.2015

Section 9: Physical and chemical properties

Appearance	:	powder
Colour	:	White to light yellow
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
9.1	14.04.2025	52737-00021	Date of first issue: 02.02.2015

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics
Particle size : No data available

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Skin corrosion/irritation

Not classified based on available information.

Components:**Interferon alfa-2b:**

Species : Rat

Result : Skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Interferon alfa-2b:**

Species : Rabbit

Remarks : slight irritation

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
9.1	14.04.2025	52737-00021	Date of first issue: 02.02.2015

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Interferon alfa-2b:**

Genotoxicity in vitro	:	Test Type: Chromosome aberration test in vitro Result: negative
		Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Result: negative Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:**Interferon alfa-2b:**

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Monkey Fertility: LOAEL: 3.8 µg/kg Result: menstrual irregularities Remarks: Abortion
Effects on foetal development	:	Test Type: Fertility/early embryonic development Species: Monkey Developmental Toxicity: LOAEL: 3.8 µg/kg body weight Result: Embryolethal effects
Reproductive toxicity - Assessment	:	May damage fertility. May damage the unborn child.

STOT - single exposure

Not classified based on available information.

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
9.1	14.04.2025	52737-00021	Date of first issue: 02.02.2015

STOT - repeated exposure

May cause damage to organs (Blood, Bone marrow) through prolonged or repeated exposure.

Components:**Interferon alfa-2b:**

Target Organs	:	Blood, Bone marrow
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Interferon alfa-2b:**

Species	:	Monkey
NOAEL	:	0.095 mg/kg
Application Route	:	Intramuscular
Exposure time	:	1 Months
Remarks	:	No significant adverse effects were reported

Species	:	Rat
NOAEL	:	0.38 mg/kg
Application Route	:	Subcutaneous
Exposure time	:	3 Months
Remarks	:	No significant adverse effects were reported

Species	:	Mouse
NOAEL	:	0.076 mg/kg
Application Route	:	Intraperitoneal
Exposure time	:	9 d
Remarks	:	No significant adverse effects were reported

Species	:	Monkey
LOAEL	:	0.38 mg/kg
Application Route	:	Intramuscular
Exposure time	:	3 Months
Target Organs	:	Blood, Bone marrow
Remarks	:	Significant toxicity observed in testing

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Interferon alfa-2b:**

Skin contact	:	Symptoms: The most common side effects are:, flu-like symptoms, Fever, chills, Fatigue
--------------	---	--

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
9.1	14.04.2025	52737-00021	Date of first issue: 02.02.2015

Section 12: Ecological information**Ecotoxicity**

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

IATA-DGR

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

IMDG-Code

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
9.1	14.04.2025	52737-00021	Date of first issue: 02.02.2015

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
EmS Code	: Not applicable
Marine pollutant	: Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Hazchem Code	: Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
9.1	14.04.2025	52737-00021	Date of first issue: 02.02.2015

Section 16: Other information

Revision Date : 14.04.2025

Further informationSources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their

Interferon Alfa-2b Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
9.1	14.04.2025	52737-00021	Date of first issue: 02.02.2015

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN